Literature DB >> 16611025

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

F Ghanbari1, K Rowland-Yeo, J C Bloomer, S E Clarke, M S Lennard, G T Tucker, A Rostami-Hodjegan.   

Abstract

The published literature on mechanism based inhibition (MBI) of CYPs was evaluated with respect to experimental design, methodology and data analysis. Significant variation was apparent in the dilution factor, ratio of preincubation to incubation times and probe substrate concentrations used, and there were some anomalies in the estimation of associated kinetic parameters (k(inact), K(I), r). The impact of the application of inaccurate values of k(inact) and K(I) when extrapolating to the extent of inhibition in vivo is likely to be greatest for those compounds of intermediate inhibitory potency, but this also depends on the fraction of the net clearance of substrate subject to MBI and the pre-systemic and systemic exposure to the inhibitor. For potent inhibitors, the experimental procedure is unlikely to have a material influence on the maximum inhibition. Nevertheless, the bias in the values of the kinetic parameters may influence the time for recovery of enzyme activity following re-synthesis of the enzyme. Careful attention to the design of in vitro experiments to obtain accurate kinetic parameters is necessary for a reliable prediction of different aspects of the in vivo consequences of MBI. The review calls for experimental studies to quantify the impact of study design in studies of MBI, with a view to better harmonisation of protocols.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611025     DOI: 10.2174/138920006776359293

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  13 in total

1.  Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes.

Authors:  Haiyan Li; Jin Sun; Xiaofan Sui; Zhongtian Yan; Yinghua Sun; Xiaohong Liu; Yongjun Wang; Zhonggui He
Journal:  AAPS J       Date:  2009-05-14       Impact factor: 4.009

Review 2.  In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.

Authors:  Stephen Fowler; Hongjian Zhang
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

Review 3.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

4.  Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole.

Authors:  Jeannine Chan; Tyler Oshiro; Sarah Thomas; Allyson Higa; Stephen Black; Aleksandar Todorovic; Fawzy Elbarbry; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2016-02-05       Impact factor: 3.922

5.  In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

Authors:  Thomas M Polasek; Janani S Sadagopal; David J Elliot; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12-11       Impact factor: 2.953

6.  The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.

Authors:  Yasushi Yoshigae; Chitra Sridar; Ute M Kent; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

7.  Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.

Authors:  Thomas M Polasek; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

8.  Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.

Authors:  Laura K Hinton; Aleksandra Galetin; J Brian Houston
Journal:  Pharm Res       Date:  2007-09-27       Impact factor: 4.200

Review 9.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

10.  Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.

Authors:  Justin D Lutz; Brooke M VandenBrink; Katipudi N Babu; Wendel L Nelson; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-06-19       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.